Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes

被引:17
作者
Atmaca, Aysegul [1 ]
Gedik, Olcay [1 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Endocrinol & Metab, Ankara, Turkey
关键词
diabetic nephropathy; microalbuminuria; ACE inhibitors; ATII receptor blockers; renoprotection;
D O I
10.1007/BF02850049
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The goal of this study was to compare the effects of lisinopril, losartan, and their combination on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Patients were randomly assigned to 3 groups: group I (n=9), group 2 (n=9), and group 3 (n=8) received 10 mg lisinopril, 50 mg losartan, and 10 mg lisinopril plus 50 mg losartan, respectively, each day. For 12 mo, the 24-h urine albumin excretion rate was assessed at 3-mo intervals. At study completion, the urine albumin excretion rate had been reduced significantly in each group (P=.001); however, no significant differences were noted among groups (P=.587). Investigators in the present study have concluded that lisinopril, losartan, and their combination have similar effects on microalbuminuria in normotensive patients with type 2 diabetes mellitus, and that combination therapy does not provide additional benefit.
引用
收藏
页码:615 / 622
页数:8
相关论文
共 50 条
[31]   Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer [J].
Asgharzadeh, Fereshteh ;
Geraylow, Kiarash Roustai ;
Khazaei, Majid ;
Nassiri, Mohammadreza ;
Hassanian, Seyed Mahdi ;
Ferns, Gordon A. ;
Avan, Amir .
CURRENT CANCER DRUG TARGETS, 2022, 22 (10) :785-795
[32]   Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review [J].
Mc Menamin, Una C. ;
Murray, Liam J. ;
Cantwell, Marie M. ;
Hughes, Carmel M. .
CANCER CAUSES & CONTROL, 2012, 23 (02) :221-230
[33]   Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease [J].
Ripley, Elizabeth .
AMERICAN HEART JOURNAL, 2009, 157 (06) :S7-S16
[34]   Association between angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and major psychiatric disorders [J].
Hu, Wei-Syun ;
Lin, Cheng-Li .
JOURNAL OF AFFECTIVE DISORDERS, 2021, 289 :16-20
[35]   Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19 [J].
Khalili, Azadeh ;
Karim, Hosein ;
Bayat, Gholamreza .
IRANIAN JOURNAL OF MEDICAL SCIENCES, 2021, 46 (04) :312-316
[36]   Renoprotective Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria [J].
Hsu, Feng-Yi ;
Lin, Fang-Ju ;
Ou, Huang-Tz ;
Huang, Shih-Hui ;
Wang, Chi-Chuan .
KIDNEY & BLOOD PRESSURE RESEARCH, 2017, 42 (02) :358-368
[37]   Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes [J].
Rosen, AB ;
Karter, AJ ;
Liu, JY ;
Selby, JV ;
Schneider, EC .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 (06) :669-675
[38]   Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes [J].
Allison B. Rosen ;
Andrew J. Karter ;
Jennifer Y. Liu ;
Joe V. Selby ;
Eric C. Schneider .
Journal of General Internal Medicine, 2004, 19 :669-675
[39]   Effect of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin Receptor Blockers on the Prevention of Death in Patients with Type 2 Diabetes and Undetermined Nephropathy : Five-Year Survival Data [J].
Mongkolsomlit, Sirima ;
Rawdaree, Petch ;
Komoltri, Chulalux ;
Tawichasri, Chamaiporn ;
Patumanond, Jayanton .
JOURNAL OF DIABETES & METABOLISM, 2012, 3 (04)
[40]   Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Kidney Disease [J].
Robert C. Stanton .
Current Diabetes Reports, 2013, 13 :567-573